Canadian Urological Association best practice report: Diagnosis and management of nocturia

Laura N. Nguyen; Harkanwal Randhawa; Geneviève Nadeau; Ashley Cox; Duane Hickling; Lysanne Campeau; Juliana Li; Blayne Welk; Kevin Carlson

doi:10.5489/cuaj.7970

Canadian Urological Association best practice report: Diagnosis and management of nocturia

Laura N. Nguyen, Harkanwal Randhawa, Geneviève Nadeau, Ashley Cox, Duane Hickling, Lysanne Campeau, Juliana Li, Blayne Welk, Kevin Carlson

Medicine

Research output: Contribution to journal › Review article › peer-review

6 Citations (Scopus)

Abstract

Nocturia remains a difficult-to-treat symptom with significant impact on not just quality of life but also morbidity and mortality. It has classically been considered a symptom of the lower urinary tract, and thus has been most commonly managed by urologists. However, the majority of patients have nocturia due at least in part to NP, and many have multiple contributing factors resulting in their symptoms. These multifactorial etiologies are best managed by a multidisciplinary team led by primary care physicians and urologists, and involving geriatricians, sleep specialists, pulmonologists, cardiologists, and endocrinologists as needed. Regardless of etiology, a large proportion of patients respond well to conservative strategies, including behavioral and lifestyle modifications.

Original language	English
Pages (from-to)	E336-E349
Journal	Journal of the Canadian Urological Association
Volume	16
Issue number	7
DOIs	https://doi.org/10.5489/cuaj.7970
Publication status	Published - Jul 2022

Bibliographical note

Funding Information:
Competing interests: Dr. Nguyen has been a speaker for Astellas and Pfizer. Dr. Nadeau has been an advisory board member for Allergan, Astellas, Boston Scientific, Ferring, and Pfizer; has been a speaker for Allergan, Astellas, Boston Scientific, Ferring, Laborie, Pfizer, Red Leaf Medical, and Searchlight Pharma; has received payment from Allergan, Boston Scientific, Red Leaf Medical, and Searchlight Pharma (preceptorships); and has received a research grant from Pfizer. Dr. Cox has been an advisory board member for Astellas, Pfizer, and TEVA; a speaker for Astellas and Pfizer; and is the site lead of a clinical trial supported by Aquinox. Dr. Campeau has been an advisory board member for Allergan, Astellas, and Coloplast; and has been a speaker for Astellas and Coloplast. Dr. Carlson has been an advisory board member for and received honoraria from Abbvie. The remaining authors do not report any competing personal or financial interests related to this work.

Publisher Copyright:
© 2022 Canadian Urological Association.

ASJC Scopus Subject Areas

Oncology
Urology

PubMed: MeSH publication types

Journal Article

Access to Document

10.5489/cuaj.7970

Cite this

@article{012655f62a5f4bbbb9271f2b66ae3adf,

title = "Canadian Urological Association best practice report: Diagnosis and management of nocturia",

abstract = "Nocturia remains a difficult-to-treat symptom with significant impact on not just quality of life but also morbidity and mortality. It has classically been considered a symptom of the lower urinary tract, and thus has been most commonly managed by urologists. However, the majority of patients have nocturia due at least in part to NP, and many have multiple contributing factors resulting in their symptoms. These multifactorial etiologies are best managed by a multidisciplinary team led by primary care physicians and urologists, and involving geriatricians, sleep specialists, pulmonologists, cardiologists, and endocrinologists as needed. Regardless of etiology, a large proportion of patients respond well to conservative strategies, including behavioral and lifestyle modifications.",

author = "Nguyen, {Laura N.} and Harkanwal Randhawa and Genevi{\`e}ve Nadeau and Ashley Cox and Duane Hickling and Lysanne Campeau and Juliana Li and Blayne Welk and Kevin Carlson",

note = "Funding Information: Competing interests: Dr. Nguyen has been a speaker for Astellas and Pfizer. Dr. Nadeau has been an advisory board member for Allergan, Astellas, Boston Scientific, Ferring, and Pfizer; has been a speaker for Allergan, Astellas, Boston Scientific, Ferring, Laborie, Pfizer, Red Leaf Medical, and Searchlight Pharma; has received payment from Allergan, Boston Scientific, Red Leaf Medical, and Searchlight Pharma (preceptorships); and has received a research grant from Pfizer. Dr. Cox has been an advisory board member for Astellas, Pfizer, and TEVA; a speaker for Astellas and Pfizer; and is the site lead of a clinical trial supported by Aquinox. Dr. Campeau has been an advisory board member for Allergan, Astellas, and Coloplast; and has been a speaker for Astellas and Coloplast. Dr. Carlson has been an advisory board member for and received honoraria from Abbvie. The remaining authors do not report any competing personal or financial interests related to this work. Publisher Copyright: {\textcopyright} 2022 Canadian Urological Association.",

year = "2022",

month = jul,

doi = "10.5489/cuaj.7970",

language = "English",

volume = "16",

pages = "E336--E349",

journal = "Journal of the Canadian Urological Association",

issn = "1911-6470",

publisher = "Canadian Medical Association",

number = "7",

}

TY - JOUR

T1 - Canadian Urological Association best practice report

T2 - Diagnosis and management of nocturia

AU - Nguyen, Laura N.

AU - Randhawa, Harkanwal

AU - Nadeau, Geneviève

AU - Cox, Ashley

AU - Hickling, Duane

AU - Campeau, Lysanne

AU - Li, Juliana

AU - Welk, Blayne

AU - Carlson, Kevin

N1 - Funding Information: Competing interests: Dr. Nguyen has been a speaker for Astellas and Pfizer. Dr. Nadeau has been an advisory board member for Allergan, Astellas, Boston Scientific, Ferring, and Pfizer; has been a speaker for Allergan, Astellas, Boston Scientific, Ferring, Laborie, Pfizer, Red Leaf Medical, and Searchlight Pharma; has received payment from Allergan, Boston Scientific, Red Leaf Medical, and Searchlight Pharma (preceptorships); and has received a research grant from Pfizer. Dr. Cox has been an advisory board member for Astellas, Pfizer, and TEVA; a speaker for Astellas and Pfizer; and is the site lead of a clinical trial supported by Aquinox. Dr. Campeau has been an advisory board member for Allergan, Astellas, and Coloplast; and has been a speaker for Astellas and Coloplast. Dr. Carlson has been an advisory board member for and received honoraria from Abbvie. The remaining authors do not report any competing personal or financial interests related to this work. Publisher Copyright: © 2022 Canadian Urological Association.

PY - 2022/7

Y1 - 2022/7

N2 - Nocturia remains a difficult-to-treat symptom with significant impact on not just quality of life but also morbidity and mortality. It has classically been considered a symptom of the lower urinary tract, and thus has been most commonly managed by urologists. However, the majority of patients have nocturia due at least in part to NP, and many have multiple contributing factors resulting in their symptoms. These multifactorial etiologies are best managed by a multidisciplinary team led by primary care physicians and urologists, and involving geriatricians, sleep specialists, pulmonologists, cardiologists, and endocrinologists as needed. Regardless of etiology, a large proportion of patients respond well to conservative strategies, including behavioral and lifestyle modifications.

AB - Nocturia remains a difficult-to-treat symptom with significant impact on not just quality of life but also morbidity and mortality. It has classically been considered a symptom of the lower urinary tract, and thus has been most commonly managed by urologists. However, the majority of patients have nocturia due at least in part to NP, and many have multiple contributing factors resulting in their symptoms. These multifactorial etiologies are best managed by a multidisciplinary team led by primary care physicians and urologists, and involving geriatricians, sleep specialists, pulmonologists, cardiologists, and endocrinologists as needed. Regardless of etiology, a large proportion of patients respond well to conservative strategies, including behavioral and lifestyle modifications.

UR - http://www.scopus.com/inward/record.url?scp=85139012599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85139012599&partnerID=8YFLogxK

U2 - 10.5489/cuaj.7970

DO - 10.5489/cuaj.7970

M3 - Review article

C2 - 35819914

AN - SCOPUS:85139012599

SN - 1911-6470

VL - 16

SP - E336-E349

JO - Journal of the Canadian Urological Association

JF - Journal of the Canadian Urological Association

IS - 7

ER -

Canadian Urological Association best practice report: Diagnosis and management of nocturia

Abstract

Bibliographical note

ASJC Scopus Subject Areas

PubMed: MeSH publication types

Access to Document

Other files and links

Fingerprint

Cite this